skip to main content

Ovarian Cancer — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardGynaecological CancersOvarian CancerSCE Medical Oncology

At the planned week-4 dose of pegylated liposomal doxorubicin for ovarian cancer, a patient has grade 2 palmar-plantar erythrodysaesthesia: painful erythema and small blisters interfere with activities but do not prevent them. What does the UK SmPC dose table advise?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Delay weekly; if grade 2 persists at week 6, reduce by 25% and resume the 4-week interval

The best answer is “Delay weekly; if grade 2 persists at week 6, reduce by 25% and resume the 4-week interval”. For grade 2 PPE at week 4, the UK SmPC says to delay one week and delay again if present at week 5. Persistence at week 6 requires a 25% reduction and return to the 4-week schedule, not discontinuation or a 50% reduction.

Reference: Pegylated liposomal doxorubicin UK Summary of Product Characteristics: https://www.medicines.org.uk/emc/product/12931/smpc